Clinical trialPhase 2 / Phase 3Completed
Nimotuzumab in Adults With Pancreatic Cancer
A RANDOMIZED, MULTICENTER, PHASE IIB/IIIA STUDY OF GEMCITABINE AND THE MONOCLONAL ANTIBODY NIMOTUZUMAB (OSAG 101) VERSUS GEMCITABINE AND PLACEBO FOR THE TREATMENT OF CHEMOTHERAPY-NAIVE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER
- Outcome
- Finished, no results posted
- Phase
- Phase 2 / Phase 3
- Status
- Completed
- Study type
- Interventional
- Start
- September 2007
- Expected end
- January 2014
- Enrollment
- 188 participants
- Sites
- 1
- Primary outcomes
- Time to tumor progression (TTP) and overall survival (OS) in chemotherapy-naive patients. To assess the efficacy of Nimotuzumab as add on therapy to Gemcitabine in comparison with Gemcitabine and placebo
- Sponsor
- Industry
- Results posted
- No
- Last update
- 15 October 2015
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try